Polatuzumab vedotin-piiq
Polatuzumab vedotin-piiq Uses, Dosage, Side Effects, Food Interaction and all others data.
Polatuzumab vedotin-piiq is a CD79b specific antibody conjugated to the antineoplastic agent monomethyl auristatin E. This medication was granted accelerated FDA approval on 10 June 2019.
The binding of the unconjugated drug to microtubules in B cells leads to a number of immunosuppressant adverse effects including neutropenia and thrombocytopenia.
The incidence of peripheral neuropathy also increases with increasing doses and time exposed to the drug.
| Trade Name | Polatuzumab vedotin-piiq |
| Generic | Polatuzumab vedotin |
| Polatuzumab vedotin Other Names | Polatuzumab vedotin, polatuzumab vedotin-piiq |
| Type | Intravenous |
| Weight | 149987.0 Da (Approximate, Complex) |
| Protein binding | In vitro studies of monomethyl auristatin E show that it is 71-77% bound to plasma proteins. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Polatuzumab vedotin-piiq is a CD79b antibody conjugate indicated to treat relapsed or refractory B-cell lymphoma.
This medication is indicated to treat adults with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more previous therapies.
Polatuzumab vedotin-piiq is also used to associated treatment for these conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
How Polatuzumab vedotin-piiq works
Polatuzumab vedotin-piiq is an antibody targeted to CD79b conjugated to the antineoplastic agent monomethyl auristatin E (MMAE). The antibody binds to CD79b on the surface of B cells, causing the conjugate to be endocytosed. Once inside the cell, lysosomal proteases cleave the link between MMAE and the antibody allowing MMAE to bind to microtubules, inhibit cell division, and induce apoptosis.
Toxicity
Data regarding overdoses and LD50 are not readily available.
In animal studies, embryo-fetal morality and birth defects were observed at less than the recommended dose and so the risk to the fetus must be weighed against the benefit to the mother. There is currently no data for the effects of polatuzumab vedotin on human pregnancies, though women are advised to used contraception while taking this medication.
Women are advised not to breastfeed until 2 months after their last dose due to the potential risk to the infant, however no data is available regarding the effects of polatuzumab vedotin on the child or if it is present in breastmilk.
Studies have not been performed to determine the carcinogenicity of this medication. Monomethyl auristatine E (MMAE) appears to be genotoxic in in vivo experiments but is not mutagenic in any tests performed. Based on animal data, polatuzumab vedotin may adversely affect male fertility and it is not known if this effect would be reversible.
Food Interaction
No interactions found.Volume of Distribution
The central volume of distribution is 3.15L.
Elimination Route
Antibody conjugated monomethyl auristatin E (MMAE) reaches a maximum concentration of 803±233ng/mL while unconjugated MMAE reaches a maximum concentration of 6.82±4.73ng/mL. The area under the curve for the conjugated medication is 1860±966day*ng/mL and 52.3±18.0day*ng/mL for the unconjugated medication.
Because doses are delivered intravenously, a bioavailability value is not available.
Half Life
The antibody conjugated monomethyl auristatin E has a terminal half life of 12 days.
Clearance
0.9L/day.
Elimination Route
The polatuzumab vedotin's antibody is likely to be metabolized into small peptides and amino acids meaning it's route of eliminate is likely to be mainly hepatic as it is a protein of approximately 150kDa.
The conjugated antineoplastic agent, monomethyl auristatin E, is eliminated in the urine and feces.
Innovators Monograph
You find simplified version here Polatuzumab vedotin-piiq
